CurrentUnitedHealthcarePolicy CS132ID.B

Noncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Idaho Only)

State-specific UnitedHealthcare medical policy for Idaho (including Idaho Medicaid Plus) addressing noncontact normothermic wound warming therapy (NNWT), noncontact real-time fluorescence wound imaging, and references to low-frequency ultrasound therapy for wound treatment; provides coverage rationale, evidence summary, applicable codes, device descriptions, and guidance.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Idaho Only)

Policy CodePolicy CS132ID.B

Change TypeState-specific criteria added; supporting info updated

Effective DateAug 1, 2025

Next Review Date

Key ActionVerify member's state plan (Idaho) before applying coverage determinations and refer to the Idaho Medicaid Provider Handbook, Therapy Services, Chapter 5.1 for low-frequency ultrasound clinical criteria.

POLICY UPDATE CHANGES

Coverage Rationale State-Specific Criteria added instruction to

Coverage Rationale State-Specific Criteria added instructing referral to the Idaho Medicaid Provider Handbook for clinical coverage criteria for low-frequency ultrasound therapy.

Non state-specific criteria removed language stating low-frequency ultrasound therapy is unproven and not medically necessary due to insufficient evidence.

Supporting Information updated: Description of Services, Clinical Evidence, and References sections revised to reflect current information and literature.

Archived previous policy version CS132ID.A.

Coverage Summary

State-specific UnitedHealthcare medical policy for Idaho (including Idaho Medicaid Plus) addressing noncontact normothermic wound therapy (NNWT), noncontact real-time fluorescence wound imaging (e.g., MolecuLight iX), and references to low-frequency ultrasound therapy for wound treatment. Effective date: August 1, 2025. Status: CURRENT.

High-level coverage determinations: NNWT (warming therapy) is unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy; noncontact real-time fluorescence wound imaging for bacterial detection (e.g., MolecuLight iX) is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy. Low-frequency ultrasound therapy is addressed with separate state-specific clinical criteria (refer to the Idaho-specific criteria and Idaho Medicaid Provider Handbook for medical necessity requirements).

Key facts

Effective dateAugust 1, 2025

Policy numberCS132ID.B

SubjectNoncontact warming therapy, ultrasound therapy, and fluorescence imaging for wounds (Idaho)

State limitationThis medical policy applies only to the state of Idaho, including Idaho Medicaid Plus plans.

Stats - Technologies addressed2 (NNWT, Fluorescence Imaging)

Stats - State-specific policy (Idaho)1

Stats - References cited in this part9

Medical-Necessity Criteria

Coverage determinations / Medical necessity

Policy statements regarding medical necessity and investigational status for specified wound therapies:

This medical policy applies only to the state of Idaho, including Idaho Medicaid Plus plans.

For medical necessity clinical coverage criteria for low frequency ultrasound therapy for treating wounds, refer to the (separate) state-specific criteria.

Low frequency ultrasound criteria are referenced but not included in this document (see separate policy).

Warming therapy or noncontact normothermic wound therapy (NNWT) is unproven and not medically necessary for treating wounds due to insufficient evidence of efficacy.

Noncontact real-time fluorescence wound imaging for bacterial presence is unproven and not medically necessary due to insufficient evidence of safety and/or efficacy.

Not Medically Necessary / Investigational

NNWT unproven and not medically necessary

Defined as noncontact normothermic wound therapy using a wound cover and warming unit to raise wound temperature and maintain humidity.

Noncontact fluorescence imaging unproven and not medically necessary

Includes handheld real-time fluorescence wound imaging devices for bacterial detection (e.g., MolecuLight iX).

Note: Clinical coverage criteria for low-frequency ultrasound therapy are provided in a separate, state-specific policy (refer to Idaho Medicaid Provider Handbook; Therapy Services, Chapter 5.1: Active Wound Care Management).

Coding

Procedure / CPT/HCPCS codes referencedmixed

0598T	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; first anatomic site (e.g., lower extremity)
97610	Noncontact real-time fluorescence wound imaging, for bacterial presence, location, and load, per session; each additional anatomic site (e.g., upper extremity) (List separately in addition to code for primary procedure).
97610	Low frequency, non-contact; non-thermal ultrasound, including topical application(s), when performed, wound assessment; and instruction(s) for ongoing care, per day
A6000	Noncontact wound-warming wound cover for use with the noncontact wound-warming device and warming card
E0231	Noncontact wound-warming device (temperature control unit; AC adapter and power cord) for use with warming card and wound cover
E0232	Warming card for use with the noncontact wound-warming device and noncontact wound warming- wound cover

Provider Actions

Documentation Required

State-limited applicability

Ensure policy applicability: this policy applies only to Idaho members (including Idaho Medicaid Plus); verify member's state plan before applying coverage determinations.

Applies only to Idaho members (including Idaho Medicaid Plus); verify member state plan

Prior Authorization

Low frequency ultrasound therapy clinical criteria reference

Refer to the state-specific medical necessity clinical coverage criteria (separate policy) for low frequency ultrasound therapy prior authorization and medical necessity requirements.

Affected code(s): 97610

Background and Evidence Summary

Background: This policy describes NNWT (a therapy using a noncontact wound cover and warming unit to apply radiant heat and maintain high humidity to raise wound temperature) and handheld fluorescence imaging (MolecuLight iX), a violet-light, point-of-care device that visualizes fluorescent bacterial signals to aid wound assessment and documentation.

Regulatory and guideline context: The MolecuLight iX device has received FDA 510(k) clearance (informational only). Clinical guideline assessments note limited evidence: NICE concluded there is limited evidence regarding whether MolecuLight iX reduces wound closure time or improves antibiotic stewardship (MIB212, 2020), and professional guidelines (AAWC) state that warming therapy has insufficient evidence of healing efficacy to inform management decisions.

Evidence summary: Systematic reviews and trials report limited, small-sample, and inconclusive evidence for NNWT and for fluorescence imaging. For NNWT, a 2018 systematic review found no RCTs of local warming therapy versus standard care and highlighted lack of robust evidence. For MolecuLight iX, an ECRI assessment (2021, updated 2024) found evidence inconclusive and insufficient to determine improvement in patient outcomes; multiple small observational studies and pilot RCTs suggest increased detection sensitivity but do not definitively demonstrate improved clinical outcomes. Further well-designed randomized trials are needed.

Citation	Key Finding
Yue et al. 2018	Systematic review found no RCTs of local warming therapy vs standard care; evidence insufficient to draw conclusions.
ECRI assessment (2021; updated 2024)	Assessment concluded evidence for MolecuLight iX is inconclusive and insufficient to determine improvement in patient outcomes; additional RCTs needed.
Bhansali & Ramachandran 2019 (Randomized controlled trial)	Reported on low-frequency, noncontact airborne ultrasound therapy for neuropathic diabetic foot ulcers (small RCT evidence).
Voigt et al. 2011 (Systematic review/meta-analysis)	Analyzed low-frequency ultrasound as adjunctive therapy in chronic wound healing; limited evidence reported across trials.
Fluorescence imaging studies (Serena 2019; Rennie 2017; Raizman 2019, et al.)	Multiple observational and pilot studies show fluorescence imaging increases detection sensitivity for bacterial burden versus clinical assessment, but clinical utility for improving patient-centered outcomes remains unclear and larger RCTs are needed.

Revision History

2025-08-01policy_historyLatest

Policy history entry on 08/01/2025 lists 'Summary of Changes = Coverage Rationale State-Specific Criteria Added instruction to' (Coverage Rationale State-Specific Criteria added instruction to refer to the Idaho Medicaid Provider Handbook; Therapy Services, Chapter 5.1: Active Wound Care Management (OTIPT) for medical necessity clinical coverage criteria for low frequency ultrasound therapy for treating wounds).

2025-08-01addedLatest

Instruction added to refer to the Idaho Medicaid Provider Handbook; Therapy Services, Chapter 5.1: Active Wound Care Management (OTIPT) for medical necessity clinical coverage criteria for low frequency ultrasound therapy for treating wounds.

Policy Summary

PayerUnitedHealthcare

PolicyNoncontact Warming Therapy, Ultrasound Therapy, and Fluorescence Imaging for Wounds (for Idaho Only)

Policy CodePolicy CS132ID.B

Change TypeState-specific criteria added; supporting info updated

Effective DateAug 1, 2025

Next Review Date

On This Page

Prior Authorization

Follow state-specific coverage requirements (Idaho Medicaid)

Providers must refer to the Idaho Medicaid Provider Handbook; Therapy Services, Chapter 5.1: Active Wound Care Management (OTIPT) for medical necessity clinical coverage criteria for low-frequency ultrasound therapy when treating members covered under Idaho Medicaid.

Refer to Idaho Medicaid Provider Handbook; Therapy Services, Chapter 5.1: Active Wound Care Management (OTIPT)

Documentation Required

Reference clinical evidence when requesting coverage

When requesting coverage or adjudicating claims, consider the updated Description of Services, Clinical Evidence, and References sections which summarize current literature supporting or evaluating low-frequency ultrasound therapy for chronic wounds.

When requesting coverage or adjudicating claims, include relevant literature summarized in the policy